Appropriateness of Using Vitamin K for the Correction of INR Elevation Secondary to Hepatic Disease in Critically ill Patients: An Observational Study

Background Using vitamin K for correction of coagulopathy in critically ill patients is controversial with limited evidence. This study aims to evaluate the efficacy and safety of vitamin K in the correction of international normalized ratio (INR) elevation secondary to liver disease in critically i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Khalid Al Sulaiman, Mashael Al Mutairi, Omar Al Harbi, Alanoud Al Duraihim, Sara Aldosary, Haifa Al Khalil, Abdulrahman Al Shaya, Shmeylan Al Harbi, Nouf Alotaibi, Kholoud Al Aamer, Ramesh Vishwakarma, Mohammed Al Asiri, Ohoud Aljuhani, Abdulmalik Al Katheri, Abdulkareem M. Al Bekairy
Formato: article
Lenguaje:EN
Publicado: SAGE Publishing 2021
Materias:
Acceso en línea:https://doaj.org/article/0d4647e9cbd54c529725b3bec9aa442a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Background Using vitamin K for correction of coagulopathy in critically ill patients is controversial with limited evidence. This study aims to evaluate the efficacy and safety of vitamin K in the correction of international normalized ratio (INR) elevation secondary to liver disease in critically ill patients. Method A retrospective study of critically ill patients with coagulopathy secondary to liver disease. The primary outcome was to evaluate the association between vitamin K administration and the incidence of new bleeding events in critically ill patients with INR elevation; other outcomes were considered secondary. Patients were categorized into two groups based on vitamin K administration to correct INR elevation. The propensity score was generated based on disease severity scores and the use of pharmacological DVT prophylaxis. Results A total of 98 patients were included in the study. Forty-seven patients (48%) received vitamin K during the study period. The odds of the new bleeding event was not statistically different between groups (OR 2.4, 95% CI 0.28-21.67, P  = .42). Delta of INR reduction was observed with a median of 0.63 when the first dose is given ( P -value: <.0001). However the INR reduction with other subsequent doses of vitamin K was not statistically significant. Conclusion The administration of vitamin K for INR correction in critically ill patients with coagulopathy secondary to liver disease was not associated with a lower odds of new bleeding events. Further studies are needed to assess the value of vitamin K administration in critically ill patients with liver diseases related coagulopathy.